Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world’s leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product. Monrol,…

Read MoreMonrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

DirectMed Parts & Service Announces Partnership and Investment in Technical Prospects

DirectMed Parts & Service (“DirectMed”), a leading medical imaging parts, systems, and service company, and portfolio company of NMS Capital (“NMS”), announced today that it has acquired Technical Prospects, LLC (“Technical Prospects” or the “Company”), a leading provider of parts,…

Read MoreDirectMed Parts & Service Announces Partnership and Investment in Technical Prospects

MLCommons Releases New MLPerf Results that Highlight Growing Importance of Generative AI and Storage

Today, MLCommons, the leading open AI engineering consortium, announced new results from two MLPerf™ benchmark suites: MLPerf Inference v3.1, which delivers industry standard Machine Learning (ML) system performance benchmarking in an architecture-neutral, representative, and reproducible manner, and MLPerf Storage v0.5.…

Read MoreMLCommons Releases New MLPerf Results that Highlight Growing Importance of Generative AI and Storage

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95%…

Read MoreExai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron’s Long-Time Chief Financial Officer

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson’s appointment follows the retirement of Olivia Bloom, Geron’s…

Read MoreGeron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron’s Long-Time Chief Financial Officer

Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis

Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis (ECN), effective September 15, after nearly seven years of commercial…

Read MoreNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis

Optum and Capella University Announce New Nurse Practitioner Program To Address the Growing National Need for Skilled Clinicians

Optum, a diversified health services company, and Capella University, an accredited online university, announced a new educational program designed to address the growing need for skilled, advanced practice nurses. The collaboration will pair Capella’s unique educational capabilities with Optum’s clinical…

Read MoreOptum and Capella University Announce New Nurse Practitioner Program To Address the Growing National Need for Skilled Clinicians

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls and boys who received a three-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine,…

Read MoreLong-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

CVS Health expands access to life-saving medication naloxone by offering over-the-counter NARCAN

Following FDA approval, CVS Pharmacy® is now offering over-the-counter (OTC) naloxone, brand name NARCAN®, at more than 7,500 locations nationwide, making it easier and more discrete than ever to purchase the safe and effective antidote to opioid overdoses. What is naloxone? Available…

Read MoreCVS Health expands access to life-saving medication naloxone by offering over-the-counter NARCAN

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, and Suneet Varma, Global Oncology and U.S. President, at the…

Read MorePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference